A £37 million Bioscience Campus is to be set up at GlaxoSmithKline’s site at Stevenage, UK, with funding from the government, GlaxoSmithKline, and other partners.
In the highest value deal yet seen for a preclinical pipeline, GlaxoSmithKline plc swooped on Domantis Ltd, paying £230 million cash for the six-year-old UK Medical Research Council spin out.